Finds high rates of hepatic steatosis and fibrosis in schizophrenia patients on antipsychotics, suggesting a need for monitoring.
The present study suggests that about one-third of the schizophrenia patients on antipsychotics have hepatic steatosis and MAFLD and slightly more than one-fourth have hepatic fibrosis. These findings underscore the critical need for hepatic monitoring, including steatosis assessment, in patients receiving high-metabolic-risk antipsychotics.
No takes yet. Share an insight, caveat, or question.
Grover et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: